Rapport Therapeutics (RAPP) versus Its Competitors Critical Contrast

Rapport Therapeutics (NASDAQ:RAPP) is one of 1,073 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Rapport Therapeutics to related companies based on the strength of its earnings, valuation, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Rapport Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	4	0	3.00
Rapport Therapeutics Competitors	8461	22334	50534	1357	2.54

Rapport Therapeutics currently has a consensus price target of $32.67, suggesting a potential upside of 231.98%. As a group, “Pharmaceutical preparations” companies have a potential upside of 235.83%. Given Rapport Therapeutics’ rivals higher probable upside, analysts plainly believe Rapport Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Rapport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Rapport Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Valuation and Earnings

This table compares Rapport Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rapport Therapeutics	N/A	-$34.79 million	-0.71
Rapport Therapeutics Competitors	$9.89 billion	$136.37 million	-5.73

Rapport Therapeutics’ rivals have higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.